| Q33678321 | A risk-benefit assessment of metformin in type 2 diabetes mellitus |
| Q41107969 | Bodyweight change as an adverse effect of drug treatment. Mechanisms and management |
| Q35305506 | Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes |
| Q37663519 | Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study |
| Q40490649 | Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus |
| Q22241437 | Metformin |
| Q30862920 | Metformin for type-2 diabetes mellitus. Systematic review and meta-analysis |
| Q41277363 | Oral antidiabetic drug use in the elderly |
| Q24235718 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q27022613 | Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials |
| Q51573792 | [Value of biguanide in therapy of diabetes mellitus]. |